Barclays’s Aktis Oncology AKTS Stock Holding History

Barclays’s Portfolio AKTS Stock Details AKTS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.89M	Buy	151,696 +141,972	+1,460%	+$2.92M	﹤0.01%	1858
2026 Q1	$174K	Buy	+9,724	New	+$189K	﹤0.01%	3771

Other funds holding AKTS

MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Jupiter Topco New York $245B AUM

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Barclays's AKTS Position: Q2 2026 in Review

Barclays increased its Aktis Oncology (AKTS) stake by 1,460% in Q2 2026, buying an estimated $2.92M and bringing the position to 151,696 shares worth $4.89M. The position accounts for ﹤0.01% of the portfolio, ranked #1858.

Barclays first reported a position in AKTS in Q1 2026 and has held it in 2 quarters since. 113 funds tracked by Wall St. Rank hold AKTS as of Q2 2026.

Barclays held 151,696 shares of Aktis Oncology worth $4.89M as of Q2 2026.
Barclays bought 141,972 Aktis Oncology shares in Q2 2026, an estimated $2.92M.
Aktis Oncology made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #1858 holding.
Barclays first reported a position in Aktis Oncology in Q1 2026 and has held it in 2 quarters since.
113 funds tracked by Wall St. Rank held Aktis Oncology as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.